Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/5F988864F805EB5D7B9C3E3B9EAFE69555C48CCCF3600397F19316180729F4989192A06B2AAF6CE32456ED6383B1040Ahttp://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/5F988864F805EB5D7B9C3E3B9EAFE69555C48CCCF3600397F19316180729F4989192A06B2AAF6CE32456ED6383B1040Ahttp://www.w3.org/2000/01/rdf-schema#comment"PTPROt thus functions as an obligate haploinsufficient TS in CLL where its expression levels determine its role as a promoter or inhibitor of the tumorigenic process in mice. Partial loss of PTPROt generates the strongest disease phenotype suggesting that its intermediate expression levels in CLL are selected for."xsd:string
http://purl.uniprot.org/uniprot/#_3CDE22061E86284DF5E3056188C83C844A596725A86B02A37EE64F42AB8AE0B3755490EEC5AAE622F05D5170E46C4855http://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/5F988864F805EB5D7B9C3E3B9EAFE69555C48CCCF3600397F19316180729F4989192A06B2AAF6CE32456ED6383B1040A
http://purl.uniprot.org/uniprot/Q9JLU0http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/5F988864F805EB5D7B9C3E3B9EAFE69555C48CCCF3600397F19316180729F4989192A06B2AAF6CE32456ED6383B1040A
http://purl.uniprot.org/uniprot/#_Q9JLU0-mappedCitation-28166196http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/5F988864F805EB5D7B9C3E3B9EAFE69555C48CCCF3600397F19316180729F4989192A06B2AAF6CE32456ED6383B1040A